Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

Mie Grunnet; Ib J Christensen; Ulrik Lassen; Lars H Jensen; Magnus Lydolph; Jennifer J Knox; Mairead G McNamara; Mark Jitlal; Harpreet Wasan; John Bridgewater; Juan W Valle; Morten Mau-Sørensen

doi:10.1016/j.ejca.2015.04.011

Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

Mie Grunnet, Ib J Christensen, Ulrik Lassen, Lars H Jensen, Magnus Lydolph, Jennifer J Knox, Mairead G McNamara, Mark Jitlal, Harpreet Wasan, John Bridgewater, Juan W Valle, Morten Mau-Sørensen

17 Citations (Scopus)

Abstract

Background: Carbohydrate associated antigen (CA19-9) has been approved by the FDA as a biomarker for monitoring treatment effect in pancreatic cancer. However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer. Methods: Consecutive patients with inoperable bile duct cancer treated at a University Hospital were retrospectively included in an investigational cohort (n = 212). Three validation cohorts were established including patients 1) participating in phase I/II trials at a Danish Hospital (n = 71), 2) identified retrospectively in a Canadian cohort (n = 196) and 3) randomized in the ABC-02 trial (n = 410). Patients with a baseline CA19-9 and at least one CA19-9 value measured 10-12 weeks after the start of chemotherapy were included. Multivariate Cox regression analyses were performed.

Original language	English
Journal	European journal of cancer (Oxford, England : 1990)
Volume	51
Issue number	11
Pages (from-to)	1381-8
Number of pages	8
ISSN	0959-8049
DOIs	https://doi.org/10.1016/j.ejca.2015.04.011
Publication status	Published - Jul 2015

Keywords

Adult
Aged
Aged, 80 and over
Bile Duct Neoplasms
CA-19-9 Antigen
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Cohort Studies
Female
Humans
Male
Middle Aged
Prognosis
Prospective Studies
Randomized Controlled Trials as Topic
Retrospective Studies
Survival Analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2015.04.011

Cite this

Grunnet, M., Christensen, I. J., Lassen, U., Jensen, L. H., Lydolph, M., Knox, J. J., McNamara, M. G., Jitlal, M., Wasan, H., Bridgewater, J., Valle, J. W., & Mau-Sørensen, M. (2015). Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. European journal of cancer (Oxford, England : 1990), 51(11), 1381-8. https://doi.org/10.1016/j.ejca.2015.04.011

Grunnet, M, Christensen, IJ, Lassen, U, Jensen, LH, Lydolph, M, Knox, JJ, McNamara, MG, Jitlal, M, Wasan, H, Bridgewater, J, Valle, JW & Mau-Sørensen, M 2015, 'Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer', European journal of cancer (Oxford, England : 1990), vol. 51, no. 11, pp. 1381-8. https://doi.org/10.1016/j.ejca.2015.04.011

@article{f7e5f6ac92e94d8cb83d444d9e918e2d,

title = "Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer",

abstract = "Background: Carbohydrate associated antigen (CA19-9) has been approved by the FDA as a biomarker for monitoring treatment effect in pancreatic cancer. However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer. Methods: Consecutive patients with inoperable bile duct cancer treated at a University Hospital were retrospectively included in an investigational cohort (n = 212). Three validation cohorts were established including patients 1) participating in phase I/II trials at a Danish Hospital (n = 71), 2) identified retrospectively in a Canadian cohort (n = 196) and 3) randomized in the ABC-02 trial (n = 410). Patients with a baseline CA19-9 and at least one CA19-9 value measured 10-12 weeks after the start of chemotherapy were included. Multivariate Cox regression analyses were performed.",

keywords = "Adult, Aged, Aged, 80 and over, Bile Duct Neoplasms, CA-19-9 Antigen, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Cohort Studies, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Randomized Controlled Trials as Topic, Retrospective Studies, Survival Analysis",

author = "Mie Grunnet and Christensen, {Ib J} and Ulrik Lassen and Jensen, {Lars H} and Magnus Lydolph and Knox, {Jennifer J} and McNamara, {Mairead G} and Mark Jitlal and Harpreet Wasan and John Bridgewater and Valle, {Juan W} and Morten Mau-S{\o}rensen",

year = "2015",

month = jul,

doi = "10.1016/j.ejca.2015.04.011",

language = "English",

volume = "51",

pages = "1381--8",

journal = "European Journal of Cancer, Supplement",

issn = "0959-8049",

publisher = "Pergamon",

number = "11",

}

TY - JOUR

T1 - Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

AU - Grunnet, Mie

AU - Christensen, Ib J

AU - Lassen, Ulrik

AU - Jensen, Lars H

AU - Lydolph, Magnus

AU - Knox, Jennifer J

AU - McNamara, Mairead G

AU - Jitlal, Mark

AU - Wasan, Harpreet

AU - Bridgewater, John

AU - Valle, Juan W

AU - Mau-Sørensen, Morten

PY - 2015/7

Y1 - 2015/7

N2 - Background: Carbohydrate associated antigen (CA19-9) has been approved by the FDA as a biomarker for monitoring treatment effect in pancreatic cancer. However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer. Methods: Consecutive patients with inoperable bile duct cancer treated at a University Hospital were retrospectively included in an investigational cohort (n = 212). Three validation cohorts were established including patients 1) participating in phase I/II trials at a Danish Hospital (n = 71), 2) identified retrospectively in a Canadian cohort (n = 196) and 3) randomized in the ABC-02 trial (n = 410). Patients with a baseline CA19-9 and at least one CA19-9 value measured 10-12 weeks after the start of chemotherapy were included. Multivariate Cox regression analyses were performed.

AB - Background: Carbohydrate associated antigen (CA19-9) has been approved by the FDA as a biomarker for monitoring treatment effect in pancreatic cancer. However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer. Methods: Consecutive patients with inoperable bile duct cancer treated at a University Hospital were retrospectively included in an investigational cohort (n = 212). Three validation cohorts were established including patients 1) participating in phase I/II trials at a Danish Hospital (n = 71), 2) identified retrospectively in a Canadian cohort (n = 196) and 3) randomized in the ABC-02 trial (n = 410). Patients with a baseline CA19-9 and at least one CA19-9 value measured 10-12 weeks after the start of chemotherapy were included. Multivariate Cox regression analyses were performed.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Bile Duct Neoplasms

KW - CA-19-9 Antigen

KW - Clinical Trials, Phase I as Topic

KW - Clinical Trials, Phase II as Topic

KW - Cohort Studies

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Prospective Studies

KW - Randomized Controlled Trials as Topic

KW - Retrospective Studies

KW - Survival Analysis

U2 - 10.1016/j.ejca.2015.04.011

DO - 10.1016/j.ejca.2015.04.011

M3 - Journal article

C2 - 25971532

SN - 0959-8049

VL - 51

SP - 1381

EP - 1388

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

IS - 11

ER -

Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this